Avelumab in Merkel Cell Carcinoma: Mechanism, Clinical Evidence, and Patient Considerations
From Population Health Surveillance to Occupational Exposure Monitoring
The legacy of general health and science information has long emphasized population-level surveillance, continuous data collection, and the identification of target groups for outcome monitoring. This foundational approach, applied historically to lifestyle-related conditions such as obesity trends, established principles for tracking health determinants across diverse populations. Within this framework, occupational health surveillance emerged as a specialized domain, focusing on work-related exposures and their potential long-term effects. The transition from broad public health monitoring to workplace-specific risk assessment is a natural extension of these established methodologies. In mass production settings, workers may encounter a range of chemical and biological agents during manufacturing processes. Among these, certain pharmaceutical compounds and their intermediates require careful handling protocols. The shift in focus from general health metrics to occupational exposure concern becomes particularly relevant when considering the potential for dermal or inhalational contact with active substances. This concern is heightened in environments where production scale increases the frequency and volume of handling. The established surveillance principles—defining target populations, standardizing outcome definitions, and ensuring timely data collection—now apply to monitoring exposure levels and implementing protective measures. This pivot from population health to workplace safety underscores the need for rigorous exposure assessment without venturing into specific disease mechanisms.
Bridging Occupational Exposure to Clinical Pharmacology: Avelumab as a PD-L1 Inhibitor
Building on the principles of occupational surveillance, it is essential to understand the specific pharmacological properties of agents that may be encountered in manufacturing settings. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was the first therapeutic agent specifically approved for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/29799096/;https://pubmed.ncbi.nlm.nih.gov/36450381/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). In broader clinical experience, response rates to PD-1/PD-L1 inhibition in metastatic MCC can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality, and response to chemotherapy is not durable (https://pubmed.ncbi.nlm.nih.gov/31543781/;https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Mechanism of Action and Immune-Related Adverse Events
The mechanistic pathway linking avelumab to MCC involves blockade of the PD-L1 receptor on tumor cells or immune cells, which prevents the inhibitory signal that would otherwise suppress T-cell activity. This reactivation of the immune system enables an antitumor response against MCC cells. However, this same mechanism can lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC treated with avelumab; the hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that irAEs can occur during avelumab treatment and may require clinical management, but they do not necessarily necessitate permanent discontinuation of therapy. For patients who become refractory to avelumab, alternative treatment options are limited. In Europe, approved systemic therapies for MCC are limited to the PD-L1 inhibitor avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined therapy with ipilimumab and nivolumab has shown activity. In a multicenter study of the prospective skin cancer registry ADOREG, three out of five patients with avelumab-refractory metastatic MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A retrospective study also reported that ipilimumab plus nivolumab can be effective in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings indicate that sequential immune checkpoint inhibition may provide clinical benefit for patients who progress on avelumab.
Clinical Context and Risk Considerations for Patients
The timeline between avelumab exposure and documented health outcomes varies. In the JAVELIN Merkel 200 trial, objective responses were observed during treatment, with no specific latency period reported in the available evidence. For immune-related adverse events such as sarcoidosis reactivation, the onset can occur during active treatment, as described in the case report where hypercalcaemia developed while the patient was on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who become refractory, progression can occur during or after avelumab therapy, and subsequent response to ipilimumab plus nivolumab has been documented in retrospective analyses (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, avelumab functions as a PD-L1 inhibitor that reactivates the immune system to target MCC, with a confirmed objective response rate of approximately one-third in chemotherapy-refractory metastatic disease. Its use is associated with immune-related adverse events that require monitoring and management. For patients who progress on avelumab, combined ipilimumab and nivolumab represents a potential subsequent treatment option, as supported by retrospective data. The clinical context for affected patients includes awareness of both the therapeutic benefits and the risk of irAEs, as well as the possibility of sequential immunotherapy after avelumab failure.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
Frequently Asked Questions
What is the mechanism of action of avelumab in Merkel cell carcinoma?
Avelumab is a fully human IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1). By blocking PD-L1 on tumor cells or immune cells, it prevents the inhibitory signal that suppresses T-cell activity, thereby reactivating the immune system to mount an antitumor response against Merkel cell carcinoma cells (https://pubmed.ncbi.nlm.nih.gov/29799096/).
What are the common immune-related adverse events associated with avelumab?
Immune-related adverse events (irAEs) can occur due to overactivation of the immune system. These may include conditions such as hypercalcaemia secondary to sarcoidosis reactivation, as reported in one case. Such irAEs often require management with corticosteroids but do not necessarily require permanent discontinuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/).
What treatment options are available for patients who progress on avelumab?
For patients with avelumab-refractory metastatic Merkel cell carcinoma, combined therapy with ipilimumab and nivolumab has shown activity. Studies have reported responses in a subset of patients, suggesting that sequential immune checkpoint inhibition may provide clinical benefit (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/35877101/).
Does submitting information create an medical context-client relationship?
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.